A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
A nomogram could help to predict patients at risk of Grade 4 neutropenia during treatment, according to a study published in Clinical Genitourinary Cancer.
Nomograms are used in oncology as prediction tools to help patients and physicians make treatment decisions. The device uses an alpha-numeric code to describe something unique about the patient: genetic makeup, tumor makeup, comorbidities, social environment, etc.
Researchers from Tokyo Medical University in Japan studied 112 patients with castration-resistant prostate cancer (CRPC) who were treated with docetaxel-based systemic chemotherapy. Neutropenia is a major adverse event of docetaxel-based chemotherapy and the researchers sought to develop a nomogram for predicting Grade 4 neutropenia during the first cycle of chemotherapy.
More than half (55.4%) of the patients developed Grade 4 neutropenia in the first cycle of docetaxel-based chemotherapy. The researchers noted that there were significant differences in age, baseline white blood cell count, and baseline neutrophil count among patients with non-Grade 4 neutropenia and those with Grade 4 neutropenia.
However, there were not significant differences between the 2 groups when it came to serum prostate-specific antigen level, hemoglobin level, creatinine, albumin, Eastern Cooperative Oncology Group performance status, metastatic sites, extent of disease, and history of external beam radiotherapy to the prostate.
As a result, the researchers determined that age and baseline neutrophil counts were significant independent risk factors for severe neutropenia.
“Age and baseline neutrophil counts were significant independent risk factors for Grade 4 neutropenia,” the authors concluded. “The nomogram to predict it provides useful information for the management of patients with CRPC treated with docetaxel chemotherapy.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More